Navigation Links
Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer
Date:12/11/2009

CAMBRIDGE, Mass., Dec. 11 /PRNewswire/ -- Gwathmey, Inc., a pre-clinical contract research organization and biotechnology company specializing in cancer, staph aureus, and cardiovascular disease announces a new CEO. Gwathmey Pre-clinical Services announced today that Rosalie Dunn, Ph.D., has joined Gwathmey as Chief Executive Officer. Dr. Dunn has over 28 years of experience working with small businesses and the federal government. Prior to joining Gwathmey, Dr. Dunn managed multimillion dollar portfolios for the National Institutes of Health (NIH) which included cardiovascular devices and technologies, clinical studies, imaging applications, development of new animal models, bioengineering projects, sleep research, computer models, atherosclerotic plaque detection and classification, antiarrhythmic treatments and devices, telemetry systems and device miniaturization. While at the NIH she was Senior Scientific Administrator with the National Heart, Lung and Blood Institute (NHLBI). Dr. Dunn has held NIH-wide responsibility for developing, planning and managing small business programs. She received multiple NIH Awards of Merit as well as a Congressional Commendation for helping small businesses thrive. She has and continues to advise on statistical justification and design for experimentation, as well as formation of collaborations and partnerships between small businesses.

Dr. Dunn said "This difficult economy challenges smaller biotechnology as well as larger pharmaceutical companies, but at the same time it provides unique opportunities to forge new interrelationships that capitalize on niche expertise. In this case Gwathmey Inc. is in a prime position to provide individualized service economically and quickly. This is especially prominent in the cardiovascular and heart failure research area, as documented by Dr. Gwathmey's continued research supported by the NIH and her publications in medical research journals. It is my job to expand our strategic relationships and pursue new business initiatives for medical drug, treatment and device testing with a special emphasis in cardiovascular applications."

Dr. Dunn holds an appointment on the faculty of George Washington University Medical Center, Washington, D.C., where she continues as Adjunct Associate Professor in the Department of Computer Medicine.

Dr. Judith Gwathmey former CEO and Chief Scientific Officer for over 13 years stated "I am excited that Dr. Dunn has joined Gwathmey, Inc. She brings not only very strong business and leadership skills but also has an outstanding analytical mind. These attributes in combination with her well honed negotiating skills should result in the rapid establishment of effective and efficient working relationships with other businesses that incorporate speed and flexibility while remaining affordable and of the highest quality. Dr. Dunn represents the highest standards for quality and integrity in our industry. Having Dr. Dunn as CEO will enable me to devote greater efforts to the scientific aspects of Gwathmey, Inc.'s service portfolio that continues to grow at a rapid rate as well as manage our rapidly expanding services in the cardiovascular space."

Gwathmey, Inc. is a pre-clinical contract research organization that provides efficacy testing, safety, pharmacokinetic, early pharmacology and toxicology. For more information please visit our website at www.gwathmey.com.

SOURCE Gwathmey, Inc.


'/>"/>
SOURCE Gwathmey, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Microfluidics Chairman James N. Little, Ph.D., Announces Retirement from Board of Directors
2. WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Companys Scientific Advisory Board
3. Harry J. Guttman, Ph.D., J.D. of Stipkala LLC to Preside Over CincyBio 2009
4. Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors
5. Magid Abou-Gharbia, Ph.D., FRSC Joins LAXAI as Scientific Advisor
6. Cellular Dynamics International Appoints Leroy Hood, M.D., Ph.D., and George Church, Ph.D., to its Scientific Advisory Board
7. EGEN, Inc. Announces the Promotion of Jason Fewell, Ph.D., to Vice-President of Preclinical Research and Development
8. EGEN, Inc. Announces the Promotion of Khursheed Anwer, Ph.D., to President and Chief Scientific Officer
9. Cequent Names F. Stephen Laroux, Ph.D., Director, Immunology and Inflammatory Diseases
10. SENOMYX ANNOUNCES APPOINTMENT OF DAVID L. LINEMEYER, PH.D., AS VICE PRESIDENT, BIOLOGY
11. ALS Therapy Development Institute, the Worlds Largest Non-Profit Biotech, Appoints Steve Perrin, Ph.D., as Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)...  Imanis Life Sciences announced today the launch ... viruses for virotherapy research. These viruses are licensed ... vaccinia virus-based technology platform for research use. ... partnership with Genelux to offer researchers, for the ... in research," said Dr. Kah Whye Peng ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Greater Gift Initiative, Inc , ... Compass Research . GGI's mission is to advance global health and highlight the ... need in honor of each clinical trial volunteer. The vision of GGI is to ...
(Date:2/22/2017)... LEAWOOD, Kan. , Feb. 22, 2017  Aratana Therapeutics, ... licensing, development and commercialization of innovative biopharmaceutical products for companion ... 14, 2017 at 8:30 a.m. ET to discuss financial results ... 2016. Interested participants and investors may access ... dial-in: ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... leading medical education provider of women’s health, primary care, and specialty education, ... for Continuing Medical Education (ACCME). ACCME’s Accreditation with Commendation is a six-year ...
Breaking Biology Technology:
(Date:2/13/2017)... -- Former 9/11 Commission border counsel and Special Counsel ... of Identity Strategy Partners, LLP, today releases the ... Order: Protecting the Nation From Foreign Terrorist Entry Into ... President Trump,s ,Travel Ban, Executive Order gains more notoriety ... travel ban, it is important that our national discourse ...
(Date:2/9/2017)... 9, 2017 The biomass boiler market report ... biomass boiler market globally in terms of revenue (US$ ... The market for biomass boilers has been segmented on ... and country/region. The market based on feedstock type, has ... biogas & energy crops, urban residues, and others. On ...
(Date:2/8/2017)... AWRE ), a leading supplier of biometrics software ... year ended December 31, 2016. Revenue for ... $6.9 million in the same quarter last year. Operating income ... to $2.6 million in the fourth quarter of 2015. Net ... or $0.02 per diluted share, which compares to $1.8 million, ...
Breaking Biology News(10 mins):